Cognito Therapeutics today announced that it completed the final close of its oversubscribed Series C financing round.

Cognito's $105 million Series C will advance their pivotal FDA study, expand clinical neurology partnerships, and expand work past Alzheimer's into Parkinsons and beyond.

Cognito raised $105 million as it awaits trial data that it hopes will convince the FDA to authorize its Alzheimer’s treatment device.

With a pivotal trial readout for Cognito’s Spectris due later this year, the company anticipates launching the Alzheimer’s ...

Series C proceeds position Spectris for pivotal top-line data, regulatory submission, and launch planning ahead of a targeted ...